A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), ...

Theresa Medina, MD, associate professor of medicine-medical oncology at the University of Colorado Cancer Center, Anschutz ...

The RABBIT registry is supported by a joint, unconditional grant from AbbVie, Alfasigma, Amgen, Biocon, Bristol Myers Squibb, ...

Rezpegaldesleukin, an investigational interleukin-pathway agonist, demonstrated efficacy and safety for people with moderate ...

Researchers have found in a recent analysis reveals IL-17 inhibitors significantly increase the risk of Candida infections ...

The Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid.

Background Chronic inflammation and elevated reactive oxygen species are key contributors to hepatocellular carcinoma (HCC) ...

Compared with tezepelumab, solrikitug demonstrated unique epitope binding and superior potency across several assays.

Icotrokinra was safe and effective for improving skin clearance among patients with at least moderate psoriasis in ...

A new immune-modulating treatment has shown promising results for treating moderate to severe eczema, delivering fast itch ...

Turmeric may benefit men, improving their heart, prostate, and sexual health. Learn more about what research says and how to ...